請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58735
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 許瑞祥(Ruey-Shyang Hseu) | |
dc.contributor.author | Sheng-Yuan Huang | en |
dc.contributor.author | 黃聖元 | zh_TW |
dc.date.accessioned | 2021-06-16T08:28:12Z | - |
dc.date.available | 2019-03-18 | |
dc.date.copyright | 2014-03-18 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-01-14 | |
dc.identifier.citation | 1. WHO, World Health Organization, Cancer. http://www.who.int/cancer/en/ 2013.
2. NCI, National Cancer Institute, What is cancer? http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer 2013. 3. James D. Watson, T. A. B., Stephen P. Bell, Alexander Gann, Michael Levine, Richard Losick, and Inglis CSHLP, Molecular Biology of the Gene, 6th Edition. 2007. 4. WHO, Cancer fact sheet, World Health Organization. http://www.who.int/mediacentre/factsheets/fs297/en/index.html 2013. 5. NCI, National Cancer Institue, Understanding Cancer Series, Slide 2 Different Kinds of Cancer. http://www.cancer.gov/cancertopics/understandingcancer/cancer/page2 2013. 6. Hanahan, D.; Weinberg, Robert A., Hallmarks of Cancer: The Next Generation. Cell 2011, 144 (5), 646-674. 7. Lazebnik, Y., What are the hallmarks of cancer? Nat Rev Cancer 2010, 10 (4), 232-233. 8. Dorsam, R. T.; Gutkind, J. S., G-protein-coupled receptors and cancer. Nat Rev Cancer 2007, 7 (2), 79-94. 9. Gschwind, A.; Fischer, O. M.; Ullrich, A., The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4 (5), 361-370. 10. Blackburn, E. H., Telomerase and Cancer: Kirk A. Landon - AACR Prize for Basic Cancer Research Lecture. Molecular Cancer Research 2005, 3 (9), 477-482. 11. Shay, J. W.; Zou, Y.; Hiyama, E.; Wright, W. E., Telomerase and cancer. Human Molecular Genetics 2001, 10 (7), 677-685. 12. Cuperlovic-Culf, M.; Culf, A. S.; Touaibia, M.; Lefort, N., Targeting the latest hallmark of cancer: another attempt at ‘magic bullet’ drugs targeting cancers’ metabolic phenotype. Future Oncology 2012, 8 (10), 1315-1330. 13. Carmeliet, P.; Jain, R. K., Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473 (7347), 298-307. 14. Folkman, J., Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology 2002, 29 (6, Supplement 16), 15-18. 15. de Visser, K. E.; Eichten, A.; Coussens, L. M., Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6 (1), 24-37. 16. Liu, J.-j.; Lin, M.; Yu, J.-y.; Liu, B.; Bao, J.-k., Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Letters 2011, 300 (2), 105-114. 17. Giansanti, V.; Torriglia, A.; Scovassi, A. I., Conversation between apoptosis and autophagy: “Is it your turn or mine?”. Apoptosis 2011, 16 (4), 321-333. 18. Sun, Y.; Peng, Z.-L., Programmed cell death and cancer. Postgraduate Medical Journal 2009, 85 (1001), 134-140. 19. Elmore, S., Apoptosis: A Review of Programmed Cell Death. Toxicologic Pathology 2007, 35 (4), 495-516. 20. Wirawan, E.; Berghe, T. V.; Lippens, S.; Agostinis, P.; Vandenabeele, P., Autophagy: for better or for worse. Cell Res 2012, 22 (1), 43-61. 21. Edinger, A. L.; Thompson, C. B., Death by design: apoptosis, necrosis and autophagy. Current Opinion in Cell Biology 2004, 16 (6), 663-669. 22. Baehrecke, E. H., Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 2005, 6 (6), 505-510. 23. Maiuri, M. C.; Zalckvar, E.; Kimchi, A.; Kroemer, G., Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007, 8 (9), 741-752. 24. Kroemer, G.; Levine, B., Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 2008, 9 (12), 1004-1010. 25. Scarlatti, F.; Granata, R.; Meijer, A. J.; Codogno, P., Does autophagy have a license to kill mammalian cells? Cell Death Differ 2008, 16 (1), 12-20. 26. Shen, H.-M.; Codogno, P., Autophagic cell death: Loch Ness monster or endangered species? Autophagy 2011, 7 (5), 457-465. 27. Haupt, S.; Berger, M.; Goldberg, Z.; Haupt, Y., Apoptosis - the p53 network. Journal of Cell Science 2003, 116 (20), 4077-4085. 28. Fesik, S. W., Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005, 5 (11), 876-885. 29. Chen, H.-Y.; White, E., Role of Autophagy in Cancer Prevention. Cancer Prevention Research 2011, 4 (7), 973-983. 30. Rubinstein, A. D.; Kimchi, A., Life in the balance – a mechanistic view of the crosstalk between autophagy and apoptosis. Journal of Cell Science 2012, 125 (22), 5259-5268. 31. 台灣衛生福利部中央健康保險署, 100年全民健康保險醫療統計年報. http://www.nhi.gov.tw/webdata/webdata.aspx?menu=17&menu_id=1023&webdata_id=4289&WD_ID=1043 2011. 32. Mitra, A. P.; Datar, R. H.; Cote, R. J., Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification. Journal of Clinical Oncology 2006, 24 (35), 5552-5564. 33. Spiess, P. E.; Czerniak, B., Dual-Track Pathway of Bladder Carcinogenesis: Practical Implications. Archives of Pathology & Laboratory Medicine 2006, 130 (6), 844-852. 34. Barocas, D. A.; Clark, P. E., Bladder cancer. Current Opinion in Oncology 2008, 20 (3), 307-314 10. 35. Colombel, M.; Soloway, M.; Akaza, H.; Bohle, A.; Palou, J.; Buckley, R.; Lamm, D.; Brausi, M.; Witjes, J. A.; Persad, R., Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. European Urology Supplements 2008, 7 (10), 618-626. 36. Sylvester, R. J.; van der Meijden, A. P. M.; Oosterlinck, W.; Witjes, J. A.; Bouffioux, C.; Denis, L.; Newling, D. W. W.; Kurth, K., Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. European Urology 2006, 49 (3), 466-477. 37. Fernandez-Gomez, J.; Madero, R.; Solsona, E.; Unda, M.; Martinez-Pineiro, L.; Gonzalez, M.; Portillo, J.; Ojea, A.; Pertusa, C.; Rodriguez-Molina, J.; Camacho, J. E.; Rabadan, M.; Astobieta, A.; Montesinos, M.; Isorna, S.; Muntanola, P.; Gimeno, A.; Blas, M.; Martinez-Pineiro, J. A., Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. The Journal of urology 2009, 182 (5), 2195-2203. 38. Amling, C. L., Diagnosis and management of superficial bladder cancer. Current Problems in Cancer 2001, 25 (4), IN1-278. 39. Cookson, M. S.; Herr, H. W.; Zhang, Z.-F.; Soloway, S.; Sogani, P. C.; Fair, W. R., The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome. The Journal of Urology 1997, 158 (1), 62-67. 40. Sylvester, R. J., Natural History, Recurrence, and Progression in Superficial Bladder Cancer. The Scientific World JOURNAL 2006, 6, 2617-2625. 41. Brausi, M.; Oddens, J.; Sylvester, R.; Bono, A.; van de Beek, C.; van Andel, G.; Gontero, P.; Turkeri, L.; Marreaud, S.; Collette, S.; Oosterlinck, W., Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. European Urology 2014, 65 (1), 69-76. 42. Paterson, R. R. M., Ganoderma – A therapeutic fungal biofactory. Phytochemistry 2006, 67 (18), 1985-2001. 43. 林志彬, 靈芝的現代研究. 北京醫科大學出版社 2001. 44. Jong, S. C.; Birmingham, J. M., Medicinal Benefits of the Mushroom Ganoderma. In Advances in Applied Microbiology, Saul, L. N.; Allen, I. L., Eds. Academic Press: 1992; Vol. Volume 37, pp 101-134. 45. 許瑞祥, 靈芝的奧秘. 正義出版社 1998. 46. Zhang, M.; Cui, S. W.; Cheung, P. C. K.; Wang, Q., Antitumor polysaccharides from mushrooms: a review on their isolation process, structural characteristics and antitumor activity. Trends in Food Science & Technology 2007, 18 (1), 4-19. 47. Roslin J Thoppil, A. B., Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World Journal of Hepatology 2011, 27 (3(9)), 228-249. 48. Kino, K.; Yamashita, A.; Yamaoka, K.; Watanabe, J.; Tanaka, S.; Ko, K.; Shimizu, K.; Tsunoo, H., Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. Journal of Biological Chemistry 1989, 264 (1), 472-478. 49. Tanaka, S.; Ko, K.; Kino, K.; Tsuchiya, K.; Yamashita, A.; Murasugi, A.; Sakuma, S.; Tsunoo, H., Complete amino acid sequence of an immunomodulatory protein, ling zhi-8 (LZ-8). An immunomodulator from a fungus, Ganoderma lucidium, having similarity to immunoglobulin variable regions. Journal of Biological Chemistry 1989, 264 (28), 16372-16377. 50. Kino, K.; Mizumoto, K.; Sone, T.; Yamaji, T.; Watanabe, J.; Yamashita, A.; Yamaoka, K.; Shimizu, K.; Ko, K.; Tsunoo, H., An immunomodulating protein, Ling Zhi-8 (LZ-8) prevents insulitis in non-obese diabetic mice. Diabetologia 1990, 33 (12), 713-718. 51. Kohsuke, K.; Toshio, S.; Junko, W.; Akio, Y.; Hiroshi, T.; Hideki, M.; Hajime, T., Immunomodulator, LZ-8, prevents antibody production in mice. International Journal of Immunopharmacology 1991, 13 (8), 1109-1115. 52. Lin, Y.-L.; Liang, Y.-C.; Tseng, Y.-S.; Huang, H.-Y.; Chou, S.-Y.; Hseu, R.-S.; Huang, C.-T.; Chiang, B.-L., An immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NF-κB and MAPK pathways. Journal of Leukocyte Biology 2009, 86 (4), 877-889. 53. Hem, L. G. V. D.; Vliet, J. A. V. D.; Bocken, C. F. M.; Kino, K.; Hoitsma, A. J.; Tax, W. J. M., Ling Zhi-8 : studies of a new immunomodulating agent. Transplantation 1995, 60 (5), 428-443. 54. Wu, C.-T.; Lin, T.-Y.; Hsu, H.-Y.; Sheu, F.; Ho, C.-M.; Chen, E. I.-T., Ling Zhi-8 mediates p53-dependent growth arrest of lung cancer cells proliferation via the ribosomal protein S7-MDM2-p53 pathway. Carcinogenesis 2011, 32 (12), 1890-1896. 55. Lin, C.-H.; Sheu, G.-T.; Lin, Y.-W.; Yeh, C.-S.; Huang, Y.-H.; Lai, Y.-C.; Chang, J.-G.; Ko, J.-L., A new immunomodulatory protein from Ganoderma microsporum inhibits epidermal growth factor mediated migration and invasion in A549 lung cancer cells. Process Biochemistry 2010, 45 (9), 1537-1542. 56. Lin, C.-H.; Hsiao, Y.-M.; Ou, C.-C.; Lin, Y.-W.; Chiu, Y.-L.; Lue, K.-H.; Chang, J.-G.; Ko, J.-L., GMI, a Ganoderma Immunomodulatory Protein, Down-regulates Tumor Necrosis Factor α-Induced Expression of Matrix Metalloproteinase 9 via NF-κB Pathway in Human Alveolar Epithelial A549 Cells. Journal of Agricultural and Food Chemistry 2010, 58 (22), 12014-12021. 57. Liao, C.-H.; Hsiao, Y.-M.; Sheu, G.-T.; Chang, J. T.; Wang, P.-H.; Wu, M.-F.; Shieh, G.-J.; Hsu, C.-P.; Ko, J.-L., Nuclear translocation of telomerase reverse transcriptase and calcium signaling in repression of telomerase activity in human lung cancer cells by fungal immunomodulatory protein from Ganoderma tsugae. Biochemical Pharmacology 2007, 74 (10), 1541-1554. 58. Liao, C.-H.; Hsiao, Y.-M.; Lin, C.-H.; Yeh, C.-S.; Wang, J. C.-H.; Ni, C.-H.; Hsu, C.-P.; Ko, J.-L., Induction of premature senescence in human lung cancer by fungal immunomodulatory protein from Ganoderma tsugae. Food and Chemical Toxicology 2008, 46 (5), 1851-1859. 59. Lin, W.-H.; Hung, C.-H.; Hsu, C.-I.; Lin, J.-Y., Dimerization of the N-terminal Amphipathic α-Helix Domain of the Fungal Immunomodulatory Protein from Ganoderma tsugae (Fip-gts) Defined by a Yeast Two-hybrid System and Site-directed Mutagenesis. Journal of Biological Chemistry 1997, 272 (32), 20044-20048. 60. 林采蔆, 靈芝屬免疫調節蛋白 GMI 與 GFO-1 基因之選殖與Pichia pastoris 之異源表現 碩士論文 台灣大學微生物與生化學研究所。 2005 61. Hsin, I. L.; Ou, C.-C.; Wu, T.-C.; Jan, M.-S.; Wu, M.-F.; Chiu, L.-Y.; Lue, K.-H.; Ko, J.-L., GMI, an immunomodulatory protein from Ganoderma microsporum, induces autophagy in non-small cell lung cancer cells. Autophagy 2011, 7 (8), 873-882. 62. Hsin, I. L.; Sheu, G.-T.; Jan, M.-S.; Sun, H.-L.; Wu, T.-C.; Chiu, L.-Y.; Lue, K.-H.; Ko, J.-L., Inhibition of lysosome degradation on autophagosome formation and responses to GMI, an immunomodulatory protein from Ganoderma microsporum. British Journal of Pharmacology 2012, 167 (6), 1287-1300. 63. Sambrook, J.; Russell, D., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: 2001. 64. Boulares, A. H.; Yakovlev, A. G.; Ivanova, V.; Stoica, B. A.; Wang, G.; Iyer, S.; Smulson, M., Role of Poly(ADP-ribose) Polymerase (PARP) Cleavage in Apoptosis: CASPASE 3-RESISTANT PARP MUTANT INCREASES RATES OF APOPTOSIS IN TRANSFECTED CELLS. Journal of Biological Chemistry 1999, 274 (33), 22932-22940. 65. Nakatogawa, H.; Suzuki, K.; Kamada, Y.; Ohsumi, Y., Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol 2009, 10 (7), 458-467. 66. Klionsky, D. J. e. a., Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8 (4), 445-544. 67. Mizushima, N.; Yoshimori, T.; Levine, B., Methods in Mammalian Autophagy Research. Cell 2010, 140 (3), 313-326. 68. Pankiv, S.; Clausen, T. H.; Lamark, T.; Brech, A.; Bruun, J.-A.; Outzen, H.; Overvatn, A.; Bjorkoy, G.; Johansen, T., p62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy. Journal of Biological Chemistry 2007, 282 (33), 24131-24145. 69. Komatsu, M.; Kageyama, S.; Ichimura, Y., p62/SQSTM1/A170: Physiology and pathology. Pharmacological Research 2012, 66 (6), 457-462. 70. Matsumoto, G.; Wada, K.; Okuno, M.; Kurosawa, M.; Nukina, N., Serine 403 Phosphorylation of p62/SQSTM1 Regulates Selective Autophagic Clearance of Ubiquitinated Proteins. Molecular Cell 2011, 44 (2), 279-289. 71. Mizushima, N.; Yoshimori, T., How to Interpret LC3 Immunoblotting. Autophagy 2007, 3 (6), 542-545. 72. Chen, S.-K.; Chung, C.-A.; Cheng, Y.-C.; Huang, C.-J.; Ruaan, R.-C.; Chen, W.-Y.; Li, C.; Tsao, C.-W.; Hu, W.-W.; Chien, C.-C., Hydrostatic pressure enhances mitomycin C induced apoptosis in urothelial carcinoma cells. Urologic Oncology: Seminars and Original Investigations 2014, 32 (1), 26.e17-26.e24. 73. Tasdemir, E.; Maiuri, M. C.; Galluzzi, L.; Vitale, I.; Djavaheri-Mergny, M.; D'Amelio, M.; Criollo, A.; Morselli, E.; Zhu, C.; Harper, F.; Nannmark, U.; Samara, C.; Pinton, P.; Vicencio, J. M.; Carnuccio, R.; Moll, U. M.; Madeo, F.; Paterlini-Brechot, P.; Rizzuto, R.; Szabadkai, G.; Pierron, G.; Blomgren, K.; Tavernarakis, N.; Codogno, P.; Cecconi, F.; Kroemer, G., Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008, 10 (6), 676-687. 74. Maes, H.; Rubio, N.; Garg, A. D.; Agostinis, P., Autophagy: shaping the tumor microenvironment and therapeutic response. Trends in Molecular Medicine 2013, 19 (7), 428-446. 75. Mathew, R.; Karantza-Wadsworth, V.; White, E., Role of autophagy in cancer. Nat Rev Cancer 2007, 7 (12), 961-967. 76. Wu, Y.-T.; Tan, H.-L.; Shui, G.; Bauvy, C.; Huang, Q.; Wenk, M. R.; Ong, C.-N.; Codogno, P.; Shen, H.-M., Dual Role of 3-Methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-Kinase. Journal of Biological Chemistry 2010, 285 (14), 10850-10861. 77. Wu, Y.-T.; Tan, H.-L.; Huang, Q.; Kim, Y.-S.; Pan, N.; Ong, W.-Y.; Liu, Z.; Ong, C.-N.; Shen, H.-M., Autophagy plays a protective role during zVAD-induced necrotic cell death. Autophagy 2008, 4 (4), 457-466. 78. Ribble, D.; Goldstein, N.; Norris, D.; Shellman, Y., A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005, 5 (1), 1-7. 79. Paglin, S.; Hollister, T.; Delohery, T.; Hackett, N.; McMahill, M.; Sphicas, E.; Domingo, D.; Yahalom, J., A Novel Response of Cancer Cells to Radiation Involves Autophagy and Formation of Acidic Vesicles. Cancer Research 2001, 61 (2), 439-444. 80. Hernandez, L. D.; Houde, C.; Hoek, M.; Butts, B.; Nicholson, D. W.; Mehmet, H., Caspases and Cell Death. In eLS, John Wiley & Sons, Ltd: 2001. 81. Walsh, J. G.; Martin, S. J., Caspases, Substrates and Sequential Activation. In eLS, John Wiley & Sons, Ltd: 2001. 82. Xie, Z.; Klionsky, D. J., Autophagosome formation: core machinery and adaptations. Nat Cell Biol 2007, 9 (10), 1102-1109. 83. Mathew, R.; Karp, C. M.; Beaudoin, B.; Vuong, N.; Chen, G.; Chen, H.-Y.; Bray, K.; Reddy, A.; Bhanot, G.; Gelinas, C.; DiPaola, R. S.; Karantza-Wadsworth, V.; White, E., Autophagy Suppresses Tumorigenesis through Elimination of p62. Cell 2009, 137 (6), 1062-1075. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58735 | - |
dc.description.abstract | 泌尿上皮癌細胞(urothelial carcinoma cells)的種類有95%都是移行性上皮癌細胞(transitional cell carcinoma),而此類的癌細胞不論在化學治療或是免疫治療,都會有很高的復發機率。小孢子靈芝蛋白的免疫調節功能已經廣為人知,但是其被運用在抗癌治療的研究相對很少而且機制未明。本研究利用兩株不同的膀胱癌細胞株,BFTC-905及TSGH-8301為體外模式,以驗證小孢子靈芝蛋白對癌症之生長抑制,及對後續所引發之程序性細胞死亡進行探討。本研究證實,小孢子靈芝蛋白能夠抑制兩株受試膀胱癌細胞的生長,並且引發半胱天冬酶相關之自凋亡之程序性死亡反應。而兩株細胞的反應差異, TSGH-8301對GMI蛋白質的耐受度較BFTC-905強之原因,為能夠誘發自噬作用的保護作用與否。本研究期待能夠利用此蛋白質的免疫調節及抗癌功能於治療膀胱癌之轉譯醫學。 | zh_TW |
dc.description.abstract | At least 95% of urothelial carcinoma cells belong to transitional cell carcinoma. Chemotherapy or immunotherapy on bladder cancer both suffer from poor prognosis. While the functions of immunomodulatory proteins in Ganoderma are widely known, the knowledge of their therapeutic effects toward tumors remains scarce. In this study, we apply Ganoderma microsporum immunomodulatory protein to two different bladder cancer cell lines, BFTC-905 and TSGH-8301, to explore its effect on cell proliferation and the behind mechanisms of cell death. GMI inhibits the proliferation of both cell lines and induces apoptosis. The distinctive tolerance toward GMI on two bladder cancer cell lines is suspected to whether GMI could induce the protective mechanism, autophagy or not. We believe this novel therapy can shed new light on the studies of translational medicine toward bladder cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T08:28:12Z (GMT). No. of bitstreams: 1 ntu-103-R00b22009-1.pdf: 6310269 bytes, checksum: 75e8834f2dd051d095dbe05414dcd27d (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 摘要 I
Abstract II 目錄 III 表目錄 VII 第一章、介紹 1 第一節 癌症簡介 1 第二節 細胞程序性死亡 4 第三節 膀胱癌及其療法 5 第四節 靈芝之有效成分及其功能 6 第二章、研究動機 8 第三章、實驗流程圖 9 第四章、材料與方法 10 第一節 藥品及儀器 10 4.1.1 靈芝蛋白質 10 4.1.2 化學類藥品 10 4.1.3 細胞培養藥品 11 4.1.4 細胞培養耗材 11 4.1.5 實驗儀器 11 4.1.6 西方點墨法抗體 12 第二節 實驗方法 12 4.2.1 細胞培養及繼代 12 4.2.2 細胞存活率實驗 12 4.2.2.1 細胞之檢量線 12 4.2.2.2 細胞之半數抑制濃度之測量 13 4.2.3 細胞螢光染色 13 4.2.4 蛋白質電泳及西方點墨法 13 4.2.4.1 細胞裂解及蛋白質定量 13 4.2.4.2 十二烷基硫酸鈉聚丙烯酰胺凝膠電泳 13 4.2.4.3 蛋白質轉印 14 4.2.4.4 西方點墨法及化學冷光顯色 14 4.2.5 西方點墨法之統計定量 15 第五章、實驗結果 16 第一節 細胞生長實驗結果 16 第二節 時間軸分析顯微鏡分析 17 2.1 明視野分析 17 2.2 螢光染色分析 18 第三節 西方點墨法分析可能的路徑的相關蛋白 19 3.1 p53蛋白質之激活及半胱天冬酶-3的裂解分析 19 3.2二磷酸腺苷核糖聚合酶蛋白質之切割分析 20 3.3微管連接蛋白質輕鏈3B-I, II之轉化分析 20 3.3 p62蛋白質及磷酸化-p62(serine-403)之變化量分析 20 第六章、討論 22 第七章、結論與未來展望 29 圖表 30 參考文獻 57 | |
dc.language.iso | zh-TW | |
dc.title | 小孢子靈芝免疫調節蛋白抑制泌尿上皮癌細胞生長及調控其細胞程序性死亡機制探討 | zh_TW |
dc.title | Ganoderma microsporum immunomodulatory protein inhibits proliferation and modulates program cell death in urothelial carcinoma cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃世明(Shih-Ming Huang),楊健志(Chien-Chih Yang),簡志誠(Chih-Cheng Chien),鄭宇哲(Yu-Che Cheng) | |
dc.subject.keyword | 膀胱癌,移行性上皮癌細胞,靈芝,小孢子靈芝免疫調節蛋白質,程序性細胞死亡,轉譯醫學, | zh_TW |
dc.subject.keyword | Bladder cancer,transitional cell carcinoma,Ganoderma,Ganoderma microsporum,immunomodulatory protein (GMI),program cell death,translational medicine, | en |
dc.relation.page | 66 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-01-15 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 6.16 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。